Generic Betahistine Proves Bioequivalent to Brand for Ménière's Treatment
A crossover trial confirms a generic betahistine tablet matches its reference drug in absorption and safety, supporting clinical interchangeability.
Summary
A randomized, open-label crossover study evaluated whether a generic betahistine hydrochloride tablet (Tianfang) is bioequivalent to the reference formulation (Mylan) in healthy adults under both fasting and fed conditions. Using UPLC-MS/MS to measure plasma levels of the primary metabolite 2-pyridineacetic acid, researchers found that all pharmacokinetic parameters — Cmax, AUC0-t, and AUC0-∞ — fell within the accepted 80–125% bioequivalence window. Adverse events were mild in both groups with no serious reactions reported. The findings support using the generic formulation as a safe clinical substitute for the branded version in patients with Ménière's syndrome, potentially improving access and reducing treatment costs.
Detailed Summary
Ménière's syndrome, a chronic inner ear disorder causing vertigo, tinnitus, and hearing loss, is commonly managed with betahistine hydrochloride. Ensuring that generic versions of this drug perform identically to branded formulations is essential for safe clinical substitution and broader patient access.
This single-center, randomized, open-label, two-period crossover study enrolled 26 healthy subjects per arm to compare the test formulation (Tianfang, 8 mg) against the reference (Mylan, 8 mg) under both fasting and postprandial conditions. Plasma concentrations of 2-pyridineacetic acid — betahistine's primary metabolite — were quantified using UPLC-MS/MS, a highly sensitive analytical method suitable for low-concentration pharmacokinetic studies.
All key pharmacokinetic parameters met bioequivalence criteria: the 90% confidence intervals for Cmax, AUC0-t, and AUC0-∞ ratios (test/reference) fell within the regulatory standard of 80–125%. This was consistent across both fasting and fed states, strengthening confidence in the generic's performance under real-world dosing scenarios.
Safety profiles were acceptable in both groups. Adverse event rates were mild — fasting conditions showed 23.1% (test) vs. 19.2% (reference), and postprandial conditions showed 26.9% (test) vs. 7.7% (reference). No severe adverse reactions occurred. The slightly higher postprandial adverse event rate in the test group warrants monitoring but did not compromise the overall safety conclusion.
These results support the interchangeability of the generic betahistine tablet with the branded reference product, which may benefit healthcare systems seeking cost-effective treatment options for Ménière's syndrome. However, the study's single-center design and healthy volunteer population limit direct generalizability to older or more complex patient groups who typically require this medication.
Key Findings
- Generic betahistine (Tianfang) met all bioequivalence criteria vs. Mylan reference under fasting and fed conditions.
- 90% CIs for Cmax, AUC0-t, and AUC0-∞ all fell within the 80–125% regulatory bioequivalence window.
- Adverse events were mild across both formulations; no severe reactions occurred in either arm.
- Postprandial adverse event rate was slightly higher in the test group (26.9% vs. 7.7% reference).
- Findings support clinical interchangeability of the generic formulation for Ménière's syndrome management.
Methodology
Single-center, randomized, open-label, two-period crossover design with 26 healthy subjects per arm. Plasma levels of the metabolite 2-pyridineacetic acid were measured via UPLC-MS/MS under both fasting and postprandial conditions. Safety was assessed through adverse event monitoring, vital signs, and laboratory evaluations.
Study Limitations
The study was conducted at a single center with a small sample of 26 subjects per arm, limiting statistical power and generalizability. Healthy volunteers were used rather than the older adult patients who typically require betahistine, potentially masking age- or disease-related pharmacokinetic differences. The slightly elevated postprandial adverse event rate in the test group merits further investigation in larger, more diverse populations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: